Celldex Therapeutics
CLDX
CLDX
156 hedge funds and large institutions have $1.28B invested in Celldex Therapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
22% less capital invested
Capital invested by funds: $1.65B → $1.28B (-$367M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Holders
156
Holding in Top 10
5
Calls
$141M
Puts
$62.7M
Top Buyers
| 1 | +$24.9M | |
| 2 | +$14.7M | |
| 3 | +$13.2M | |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$10.2M |
| 5 |
CC
Commodore Capital
New York
|
+$8.02M |
Top Sellers
| 1 | -$18.6M | |
| 2 | -$14.5M | |
| 3 | -$14M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$13.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |